The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2102973
Abstract: ABSTRACT Objective To assess the association between the use of sodium–glucose cotransporter 2 inhibitor (SGLT2i) and the incidence of diabetic retinopathy (DR). Research design and methods PubMed, Medline, Embase, the Cochrane Central Register of Controlled… read more here.
Keywords: use sodium; association use; sglt2i; risk ... See more keywords
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes Care"
DOI: 10.2337/dc18-1871
Abstract: OBJECTIVE The sodium–glucose cotransporter 2 inhibitors (SGLT2i) empagliflozin and canagliflozin reduce the incidence of major adverse cardiovascular events (MACE), all-cause mortality (ACM), and renal events in cardiovascular outcomes trials, with observational real-world evidence suggesting class… read more here.
Keywords: class; placebo arm; sglt2i users; sglt2i ... See more keywords